Double Immune-Boosting combo enters trial for Tough-to-Treat bile duct cancer
NCT ID NCT07369791
Summary
This study is testing if adding a second immunotherapy drug (relatlimab) to a standard treatment improves outcomes for people with advanced bile duct cancer. About 76 patients who haven't had prior treatment for their advanced cancer will be randomly assigned to receive either the two-drug immunotherapy combo plus chemotherapy or just one immunotherapy drug plus chemotherapy. The main goal is to see which group has more patients whose tumors shrink significantly.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER(BTC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Medical University Hospital
Taichung, Taiwan
-
Kaohsiung Medical University Chung-Ho Memorial Hospital,
Kaohsiung City, Taiwan
-
MacKay Memorial Hospital
Taipei, Taiwan
-
National Cheng Kung University Hospital
Tainan, Taiwan
-
National Taiwan University Hospital
Taipei, Taiwan
-
Taichung Veterans General Hospital
Taichung, Taiwan
-
Taipei Veterans General Hospital
Taipei, Taiwan
-
Tri-Service General Hospital
Taipei, Taiwan
Conditions
Explore the condition pages connected to this study.